Modulation and intensification of a cyclophosphamide, hexamethylmelamine, doxorubicin, and cisplatin ovarian cancer regimen

Howard W. Bruckner, Carmel J. Cohen, Eric Feuer, James F. Holland

Research output: Contribution to journalArticlepeer-review

18 Scopus citations

Abstract

For 61 patients with stage III-IV carcinoma of the ovary, chemotherapy consisted first of cisplatin 50 mg/m2 on day 1, cyclophosphamide 500 mg/m2 on day 3, doxorubicin 50 mg/m2 on day 3, and hexamethylmelamine 100 mg/m2 on days 4-15 every 4 weeks. The dosages of doxorubicin and hexamethylmelamine were increased by 60 and 100%, respectively, until the nadir white blood cell counts fell to 1.0 × 109/L. This regimen was less neurotoxic and nephrotoxic than other intensive treatments and produced better therapeutic effects than did the immediate preceding Mount Sinai regimens: 1) The overall median survival was 43 months and progression-free survival was 25 months; 2) the greatest benefit occurred among patients under 50 years of age; 3) regression of large tumors increased in frequency, with 33% of tumors 2–6 cm and 16% of tumors larger than 6 cm converted to either pathologically proved remission or microscopic disease; and 4) for the first time, partial surgica debulking producing residual tumors less than 6 cm in sizt improved early survival.

Original languageEnglish
Pages (from-to)349-356
Number of pages8
JournalObstetrics and Gynecology
Volume73
Issue number3
StatePublished - Mar 1989
Externally publishedYes

Fingerprint

Dive into the research topics of 'Modulation and intensification of a cyclophosphamide, hexamethylmelamine, doxorubicin, and cisplatin ovarian cancer regimen'. Together they form a unique fingerprint.

Cite this